Back to Journals » OncoTargets and Therapy » Volume 12

Evidence to date: talazoparib in the treatment of breast cancer

Authors Exman P, Barroso-Sousa R, Tolaney SM

Received 28 February 2019

Accepted for publication 3 June 2019

Published 2 July 2019 Volume 2019:12 Pages 5177—5187

DOI https://doi.org/10.2147/OTT.S184971

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Prof. Dr. Jianmin Xu


Pedro Exman, Romualdo Barroso-Sousa, Sara M Tolaney

Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Abstract: Approximately 5–10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recently approved for use in patients with metastatic breast cancer with germline BRCA mutations after a phase III trial showed superior progression-free survival when compared to standard chemotherapy. In this review, we analyze the development of talazoparib as well as its safety profile and the potential role of the combination therapy with standard cytotoxic drugs and with novel therapies.

Keywords: talazoparib, breast cancer, BRCA mutation, homologous recombination deficiency

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]